Clinical trial readout dates for TG Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
| Phase 3 Ublituximab Relapsing Multiple Sclerosis · NCT05877963 | January 2027 Recruiting |
| Phase 2 Ublituximab Multiple Sclerosis · NCT07503873 | July 2027 Recruiting |
| Phase 2 Ublituximab Myasthenia Gravis · NCT07673744 | July 2028 Recruiting |
| Phase 2 Ublituximab Schizophrenia · NCT07680946 | December 2028 Recruiting |
| Phase 2/3 Ublituximab Relapsing Multiple Sclerosis · NCT07220252 | January 2030 Recruiting |
| Phase 3 Ublituximab Relapsing Multiple Sclerosis (RMS) · NCT04130997 | May 2032 Ongoing |
TG Therapeutics Inc. reported $557M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). It reported net income of $55M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |